Biofrontera(BFRI) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BFRI Biofrontera

Watchlist

0.9000
-0.0012-0.13%

Close Mar 25 16:00 ET

0.8501
-0.0499-5.54%

Post 20:01 ET

7.99MMarket Cap-0.28P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Benchmark Co. Maintains Biofrontera(BFRI.US) With Buy Rating, Maintains Target Price $7
Moomoo News13:31 ET · Ratings
Biofrontera's Growth Potential: Buy Rating Backed by FDA Approval and Positive Phase 3 Results
TipRanksMar 25 02:36 ET · Ratings
Biofrontera Inc. Reports Record Sales and Strategic Advances
TipRanksMar 24 20:04 ET
Biofrontera Full Year 2024 Earnings: Misses Expectations
Yahoo FinanceMar 22 10:06 ET
Express News | Biofrontera Shares Are Trading Lower After the Company Reported a FY24 Revenue Miss
BenzingaMar 21 14:03 ET
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript Summary
moomoo AIMar 21 11:27 ET · Conference Call

Comments

Teddy123

Mar 21 20:03

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

$Biofrontera (BFRI.US)$
Record-Breaking Year: Biofrontera Hits $37.3M Revenue as Cost Cuts Boost Bottom Line

Trytosaveabit

Mar 21 20:01

Nice

$Biofrontera (BFRI.US)$ Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.85) by 278.82 percent. This is a 75.27 percent increase over losses of $(13.02) per share from the same period last year. The company reported quarterly sales of $37.32 million which missed the analyst consensus estimate of $47.06 million by 20.69 percent. This is a 9.54 percent increase over sales of $34.07 million the same period last year.

Jaguar8

Mar 21 20:00

NEWS

$Biofrontera (BFRI.US)$
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Friday, 21st March at 8:00 am
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time
Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended Dece...

Teddy123

Mar 18 21:32

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and

$Biofrontera (BFRI.US)$
Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial

Jaguar8

Jan 8 23:11

NEWS

$Biofrontera (BFRI.US)$
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Biofrontera Inc. (BFRI) has achieved a significant milestone in its Phase 3 study of Ameluz-PDT for treating superficial Basal Cell Carcinoma (sBCC), with the last patient completing the 1-year follow-up in December 2024. The study, involving 187 patients, demonstrated highly statistically significant...

Market Insights

Symbol Mini Chart % Chg

Petroleo Brasileiro SA Petrobras

Unlock the Full List